Intelligent Ultrasound Group plc

Intelligent Ultrasound Group plc is a UK-based medical technology firm that develops, markets, and distributes both advanced clinical ultrasound software and medical training simulators across the United Kingdom, North America, and other international markets. The company's innovative AI-powered ultrasound software solutions include ScanNav Assist, which provides real-time image analysis for women's health examinations; ScanNav Anatomy Peripheral Nerve Block (PNB), designed to automatically identify crucial anatomical structures during PNB procedures; and ScanNav Detect, which aids in the automatic recognition of anomalies during general medical ultrasound scans. Additionally, they offer ScanNav HealthCheck, a product facilitating home-based ultrasound scanning. For medical education and skill development, Intelligent Ultrasound provides a comprehensive range of simulators. These include ScanTrainer, an educational platform that leverages actual patient scans for training in obstetrics, gynecology, general medicine, and emergency medicine; ScanNav Anatomy PNB Trainer, focused on teaching ultrasound-guided needling techniques; BodyWorks Eve, an ultra-realistic female patient simulator for interactive point-of-care ultrasound scenario training; and NeedleTrainer, an augmented reality solution for safe and realistic ultrasound-guided needling practice. Further offerings in their simulation portfolio comprise BabyWorks, a baby manikin for pediatric and neonatal point-of-care ultrasound and echocardiography; HeartWorks, a highly realistic simulator for echocardiography training; BodyWorks, a high-fidelity simulator utilized in critical, intensive, and emergency care settings; and ORSIM, a virtual environment designed for mastering advanced bronchoscopy skills. Founded in 2004, the company was formerly known as MedaPhor Group plc before adopting its current name, Intelligent Ultrasound Group plc, in January 2019. Its headquarters are located in Cardiff, United Kingdom.

Intelligent Ultrasound Group plc trades as IUG.L on LSE. The company is classified in Healthcare / Medical - Devices and reports in GBP.

The current profile places the business in Medical - Devices. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows £11.17M of revenue and -£2.58M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Intelligent Ultrasound Group plc can be compared against peers such as Advanced Oncotherapy plc, Belluscura plc, C4X Discovery Holdings plc, E-therapeutics Plc, Induction Healthcare Group PLC, Midatech Pharma plc.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of £42.62M, beta of 0.32, and return on equity of -26.5%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

IUG.L currently shows total debt of £690,000 and beta of 0.32. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.intelligentultrasound.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.